Docetaxel treatment in the elderly patient with hormone refractory prostate cancer
Victoria J SinibaldiSidney Kimmel Comprehensive Cancer Center at Johns Hopkins, Baltimore, MA, USAAbstract: Docetaxel is an anti-microtubular agent in the family of the taxanes, now FDA approved as first line chemotherapy for the treatment of hormone refractory metastatic prostate cancer. Recent dat...
Guardado en:
Autor principal: | Victoria J Sinibaldi |
---|---|
Formato: | article |
Lenguaje: | EN |
Publicado: |
Dove Medical Press
2008
|
Materias: | |
Acceso en línea: | https://doaj.org/article/461e3f974a96437bb4f7c96c98c0d964 |
Etiquetas: |
Agregar Etiqueta
Sin Etiquetas, Sea el primero en etiquetar este registro!
|
Ejemplares similares
-
Prevention and treatment of venous thromboembolism in the elderly patient
por: Enrico Tincani, et al.
Publicado: (2007) -
Carvedilol in the treatment of elderly patients with chronic heart failure
por: Klaus KA Witte, et al.
Publicado: (2008) -
Is it necessary to cure prostate cancer when it is possible? (Understanding the role of prostate inflammation resolution to prostate cancer evolution)
por: Ronald E Wheeler
Publicado: (2007) -
A brief review of moxifloxacin in the treatment of elderly patients with community-acquired pneumonia (CAP)
por: Anna M Ferrara
Publicado: (2007) -
The management of hemophilia in elderly patients
por: Massimo Franchini, et al.
Publicado: (2007)